Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 2Plasmacytoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1cc-486 1blinatumomab 1Valganciclovir 1Thiotepa 1Therapeutics 1Polymerase Chain Reaction 1Mesna 1Melphalan 1Granulocyte Colony-Stimulating Factor 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Filgrastim 1Cyclophosphamide 1Azacitidine 1Antiviral Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Large Granular Lymphocytic × cc-486 × Clear all
NCT05141682 2026-03-03

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2 Active not recruiting
11 enrolled
Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡